A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 1,506,646 shares of URGN stock, worth $16 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
1,506,646
Previous 2,449,277 38.49%
Holding current value
$16 Million
Previous $41.1 Million 53.44%
% of portfolio
0.05%
Previous 0.11%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$12.7 - $17.92 $12 Million - $16.9 Million
-942,631 Reduced 38.49%
1,506,646 $19.1 Million
Q2 2024

Aug 14, 2024

BUY
$12.72 - $19.2 $17 Million - $25.7 Million
1,337,257 Added 120.25%
2,449,277 $41.1 Million
Q1 2024

May 15, 2024

BUY
$13.81 - $19.33 $13.6 Million - $19.1 Million
986,020 Added 782.56%
1,112,020 $16.7 Million
Q4 2023

Feb 14, 2024

SELL
$10.87 - $15.93 $888,437 - $1.3 Million
-81,733 Reduced 39.35%
126,000 $1.89 Million
Q3 2023

Nov 14, 2023

BUY
$8.84 - $22.64 $1.84 Million - $4.7 Million
207,733 New
207,733 $2.91 Million
Q1 2020

May 15, 2020

SELL
$13.68 - $34.6 $3.04 Million - $7.68 Million
-222,024 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$21.11 - $34.86 $3.47 Million - $5.72 Million
164,222 Added 284.11%
222,024 $7.41 Million
Q3 2019

Nov 15, 2019

BUY
$23.83 - $36.44 $6,910 - $10,567
290 Added 0.5%
57,802 $1.38 Million
Q2 2019

Aug 14, 2019

SELL
$32.75 - $40.35 $6.75 Million - $8.32 Million
-206,087 Reduced 78.18%
57,512 $2.07 Million
Q1 2019

May 15, 2019

BUY
$35.47 - $54.55 $7.04 Million - $10.8 Million
198,599 Added 305.54%
263,599 $9.74 Million
Q4 2018

Feb 14, 2019

BUY
$38.35 - $50.39 $496,785 - $652,752
12,954 Added 24.89%
65,000 $2.8 Million
Q3 2018

Nov 14, 2018

BUY
$41.65 - $51.7 $2.17 Million - $2.69 Million
52,046 New
52,046 $2.46 Million

Others Institutions Holding URGN

About UroGen Pharma Ltd.


  • Ticker URGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,740,500
  • Market Cap $242M
  • Description
  • UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...
More about URGN
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.